DGAP-News: PAION AG / Key word(s): Product Launch
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
28.01.2021 / 07:06
The issuer is solely responsible for the content of this announcement.
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
- Approximately 40 million procedures take place annually in the U.S. that require the use of procedural sedation
- BYFAVO(TM) is the second Acacia Pharma product approved and launched in the U.S. in the last year and extends its portfolio of new products targeting unmet needs in anesthesia
Fewer than or equal to three prior lines of therapy.
Patients with untreated active brain metastases were excluded.
Enrolled patients were followed for a median period of 12.2 months. An independent blinded central review of the patients found that 124 patients had at least one measurable lesion at baseline and were evaluated for efficacy. Of these, 46 patients experienced a confirmed response (three complete responses and 43 partial responses), resulting in an objective response rate of 37.1% (95% Cl: 28.6–46.2). The median time to objective response was 1.4 months, the median duration of response was 10 months (95% CI: 6.9-11.1), and 43% of responders remained on treatment without progression. The disease control rate was 80.6% (95% Cl: 72.6–87.2).
E-Mail
(For Immediate Release Singapore January 28, 2021) In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) and who harbor KRAS p.G12C mutations, validating CodeBreak 100 s phase I results, according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Outcome in patients with advanced NSCLC on second- or third-line therapies is poor, with a response rate of less than 20% and median progression-free survival of fewer than four months. Approximately 13% of patients with lung adenocarcinomas harbor KRAS p.G12C mutations.
Sotorasib Provides Durable Clinical Benefit for Patients with NSCLC and KRAS Mutations
Exciting New Research to be Presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer’s Presidential Symposium
SINGAPORE, Jan. 28, 2021 (GLOBE NEWSWIRE) In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) and who harbor
KRAS p.G12C mutations, validating CodeBreak 100’s phase I results, according to research presented today at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Outcome in patients with advanced NSCLC on second- or third-line therapies is poor, with a response rate of less than 20% and median progression-free survival of fewer than four months. Approximately 13% of patients with lung adenocarcinomas harbor
Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 2020
Strengthening its Track Record of Successful Client Regulatory Approval Outcomes
SOUTHBOROUGH, Mass. (BUSINESS WIRE) #FDA Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)
i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe.